stockrow
Friday 6 November 2026
Export ABVX’s income statement to Excel — free account
Abivax SA Sponsored ADR
ABVX Healthcare Biotechnology
- EPS
- −98.8%
- Free cash flow
- −48.3%
- Total debt
- −98.5%
Quarter to June 2026, against a year earlier
86.19
2.01
+2.39%
Follow ABVX
Alert me
Abivax SA Sponsored ADR (ABVX) Shares outstanding
Abivax SA Sponsored ADR's shares outstanding at the end of fiscal 2025 was $69.5M, up 10.3% from $63.0M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $79.6M. Over the past ten years it has ranged from $10.2M (fiscal 2018) to $69.5M (fiscal 2025) — the current reading is the highest in ten years. Abivax SA Sponsored ADR ranks 192nd of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $69.5M | 10.28% |
| FY2024 | $63.0M | 46.39% |
| FY2023 | $43.1M | 125.57% |
| FY2022 | $19.1M | 13.94% |
| FY2021 | $16.8M | 17.11% |
| FY2020 | $14.3M | 17.46% |
| FY2019 | $12.2M | 19.71% |
| FY2018 | $10.2M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $79.6M | 0.87% |
| Mar 2026 | $79.0M | 13.57% |
| Dec 2025 | $69.5M | (4.68%) |
| Sep 2025 | $72.9M | 14.98% |
| 6 more quarters | Free account |
Against its own ten years
Low $10.2M
High $69.5M
Ten-year median
$17.9M
Current reading's percentile
100
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. compare | $143.4M |
| CYTK Cytokinetics, Incorporated compare | $132.1M |
| CORT Corcept Therapeutics Incorporated compare | $123.2M |
| SYRE Spyre Therapeutics, Inc. compare | $88.4M |
| ABVX Abivax SA Sponsored ADR | $79.6M |
| RYTM Rhythm Pharmaceuticals, Inc. compare | $69.0M |
| ORKA Oruka Therapeutics, Inc. compare | $62.9M |
| AXSM Axsome Therapeutics, Inc. compare | $52.4M |
| PRAX Praxis Precision Medicines, Inc. compare | $29.1M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item